CLAIMS

1. A composition that comprises a compound against EGF receptor and a compound against the NeuGcGM3 ganglioside for use in the treatment of cancer.
2. The composition of claim 1 wherein the compound against the EGF receptor is a monoclonal antibody that recognizes the EGFR.
3. The composition of claim 2 wherein the compound against the EGFR is a monoclonal antibody that recognizes the EGFR.
4. The composition of claim 1 wherein the compound against the EGFR is an anti-EGFR vaccine.
5. The composition of claim 1 wherein the compound against NeuGcGM3 ganglioside is a vaccine.
6. The composition of claim 5 wherein the vaccine has NeuGcGM3/VSSP as active principle.
7. The composition of claim 5 wherein the vaccine is Racotumumab anti-idiotypic vaccine adjuvated with alumina.
8. The composition of claim 1 that comprises an EGFR vaccine and a vaccine against NeuGcGM3 ganglioside.
9. The composition of claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.
10. The composition of claim 1 wherein the tumor is a cancer selected from the group comprising lung, breast, digestive system, urogenital system and sarcoma tumors derived of neuroectodermic tissue and lymphoproliferative disorders.
11. Use of a compound against EGFR and a compound against NeuGcGM3 ganglioside for the preparation of a medicament for retarding tumor growth in a patient according to the treatment regimen involving:

    (a) first administering to the patient the medicament comprising the compound against the EGFR and,

    (b) subsequently administering to the same patient the medicament comprising the compound against the NeuGcGM3 ganglioside.

12. Use of a compound against the EGFR and a compound against NeuGcGM3 ganglioside for the preparation of a medicament for retarding tumor growth in a patient according to the treatment regimen involving:

(a) first administering to the patient the medicament comprising the compound against NeuGcGM3 ganglioside and,

(b) subsequently administering to the same patient the medicament comprising the compound against EGFR.

13. Use of a compound against the EGFR and a compound against NeuGcGM3 ganglioside for the preparation of a medicament for retarding tumor growth in a patient according to the treatment regimen involving the simultaneous, staggered or alternate administration of therapies directed against EGFR and GM3 *N*-glycolyl ganglioside targets in cancer treatment:

14. Use according to any of claims 11-13, wherein the compound against the anti-EGFR is selected from the group of Nimotuzumab MAb or EGFR vaccine.

15. Use according to any of claims 11-13, wherein the compound against NeuGcGM3 ganglioside is NeuGcGM3/VSSP vaccine or anti-idiotypic Racotumumab/Alumina vaccine.

16. Use according to any of claims 1-14, wherein the dosage of the antibody against EGFR is in the range from approximately 100 to 400 mg.

17. Use according to any of claims 1-14, wherein the dose of the vaccine against EGFR is in the range from approximately 0.1 to 2 mg.

18. Use according to any of claims 1-15, wherein the dose of the NeuGcGM3 vaccine or the anti-idiotypic vaccine is in the range from approximately 0.1 to 2 mg.

19. Use of a compound against NeuGcGM3 ganglioside, and a compound against the EGFR, for the preparation of a medicament for retarding tumor growth in a patient, wherein said patient suffers from lung, breast, digestive system, urogenital system and sarcoma tumors derived of neuroectodermic tissue and lymphoproliferative disorders.
20. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional radiotherapy.
21. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional chemotherapy.
22. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional radiotherapy and chemotherapy.
23. A kit of reagents for tumor therapy in which EGFR and NeuGcGM3 ganglioside targets are co-expressed, wherein said reagent kit comprises simultaneous, staggered or alternate administration of:

(a): Compound against EGFR

(b): Compound against NeuGcGM3 ganglioside

CLAIMS

1. A composition that comprises a compound against EGF receptor and a compound against the NeuGcGM3 ganglioside for use in the treatment of cancer.
2. The composition of claim 1 wherein the compound against the EGF receptor is a monoclonal antibody that recognizes the EGFR.
3. The composition of claim 2 wherein the compound against the EGFR is a monoclonal antibody that recognizes the EGFR.
4. The composition of claim 1 wherein the compound against the EGFR is an anti-EGFR vaccine.
5. The composition of claim 1 wherein the compound against NeuGcGM3 ganglioside is a vaccine.
6. The composition of claim 5 wherein the vaccine has NeuGcGM3/VSSP as active principle.
7. The composition of claim 5 wherein the vaccine is Racotumumab anti-idiotypic vaccine adjuvated with alumina.
8. The composition of claim 1 that comprises an EGFR vaccine and a vaccine against NeuGcGM3 ganglioside.
9. The composition of claim 1 wherein the cancer is a tumor that co-expresses EGFR and NeuGcGM3 ganglioside targets.
10. The composition of claim 1 wherein the tumor is a cancer selected from the group comprising lung, breast, digestive system, urogenital system and sarcoma tumors derived of neuroectodermic tissue and lymphoproliferative disorders.
11. Use of a compound against NeuGcGM3 ganglioside, and a compound against the EGFR, for the preparation of a medicament for retarding tumor growth in a patient, wherein said patient suffers from lung, breast, digestive system, urogenital system and sarcoma tumors derived of neuroectodermic tissue and lymphoproliferative disorders.
12. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional radiotherapy.

13. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional chemotherapy.
14. Use of the pharmaceutical compositions of claims 1 to 10 in combination with conventional radiotherapy and chemotherapy.
15. A kit of reagents for tumor therapy in which EGFR and NeuGcGM3 ganglioside targets are co-expressed, wherein said reagent kit comprises simultaneous, staggered or alternate administration of:

    (a): Compound against EGFR

    (b): Compound against NeuGcGM3 ganglioside